Altimmune (NASDAQ:ALT) Earns “Buy” Rating from HC Wainwright

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 74.57% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Stifel Nicolaus began coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $20.83.

Altimmune Price Performance

ALT stock traded up $0.23 on Wednesday, hitting $6.87. 868,392 shares of the company were exchanged, compared to its average volume of 2,140,759. The stock has a market capitalization of $488.88 million, a price-to-earnings ratio of -4.44 and a beta of 0.19. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.84. The business’s fifty day moving average is $7.70 and its two-hundred day moving average is $7.17.

Altimmune (NASDAQ:ALT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same period last year, the business posted ($0.39) earnings per share. Equities research analysts expect that Altimmune will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Altimmune

Several large investors have recently bought and sold shares of the stock. B. Riley Wealth Advisors Inc. boosted its position in shares of Altimmune by 12.9% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after purchasing an additional 2,687 shares during the period. Creative Planning lifted its stake in Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after acquiring an additional 3,132 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Altimmune by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after acquiring an additional 4,772 shares in the last quarter. Larson Financial Group LLC acquired a new stake in Altimmune during the 3rd quarter worth about $31,000. Finally, The Manufacturers Life Insurance Company grew its stake in Altimmune by 30.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,973 shares of the company’s stock valued at $179,000 after acquiring an additional 6,339 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.